Zydus Cadila gets USFDA nod to market breast cancer drug

1 min read 28 Oct 2017, 03:53 PM IST

PTI

Zydus Cadila has received final approval from the USFDA to market Tamoxifen Citrate Tablets USP, a drug indicated to treat breast cancer

Zydus Cadila now has more than 165 USFDA approvals. Photo: Mint

New Delhi: Drug firm Zydus Cadila on Saturday said it has received final approval from the United States Food and Drug Administration (USFDA) to market Tamoxifen Citrate Tablets USP in the strengths of 10mg (base) and 20mg (base).

Tamoxifen Citrate Tablets USP will be manufactured at the group’s formulations manufacturing facility at SEZ in Ahmedabad, the company said in a BSE filing. The drug is indicated to treat breast cancer, the company said in the filing.

The group now has more than 165 approvals, it added.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Industry News, Banking News and Updates on Live Mint. Download The Mint News App to get Daily Market Updates.

More Less

Published: 28 Oct 2017, 03:53 PM IST

OPEN IN APP